(Q35689625)

9 August 2017

1 reference

title

GI clinical research 2002-2003: the year in review (English)

1 reference

9 August 2017

1

Michael Camilleri

1 reference

9 August 2017

language of work or name

English

0 references

publication date

1 November 2003

1 reference

Clinical Gastroenterology and Hepatology

9 August 2017

published in

1 reference

9 August 2017

volume

1

1 reference

9 August 2017

issue

6

1 reference

9 August 2017

page(s)

415-420

1 reference

First-degree relatives of patients with advanced colorectal adenomas have an increased prevalence of colorectal cancer

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900220-9

7 January 2021

A randomized trial of aspirin to prevent colorectal adenomas

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900220-9

7 January 2021

A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900220-9

7 January 2021

Aspirin and the prevention of colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900220-9

7 January 2021

Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900220-9

7 January 2021

Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900220-9

7 January 2021

Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900220-9

7 January 2021

Helicobacter pylori infection and the development of gastric cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900220-9

7 January 2021

Infliximab for the treatment of fistulas in patients with Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900220-9

7 January 2021

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900220-9

7 January 2021

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900220-9

7 January 2021

Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900220-9

7 January 2021

α4Integrins as Therapeutic Targets in Autoimmune Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900220-9

7 January 2021

Natalizumab for active Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900220-9

7 January 2021

Leukocyte adsorptive apheresis for the treatment of active ulcerative colitis: a prospective, uncontrolled, pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900220-9

7 January 2021

Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900220-9

7 January 2021

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900220-9

7 January 2021

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900220-9

7 January 2021

Imatinib mesylate--a new oral targeted therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900220-9

7 January 2021

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900220-9

7 January 2021

10.1016/S1542-3565(03)00220-9

Identifiers

DOI

1 reference

9 August 2017

1 reference